Oxibutinina EG is used to treat symptoms of an overactive bladder, such as incontinence (loss of bladder control) or a frequent need to urinate.
Oxibutinina EG belongs to the group of medicines called antispasmodics. It helps decrease muscle spasms of the bladder and the frequent urge to urinate caused by these spasms.
Oxibutinina EG extended-release tablets is also used to treat children 6 years of age and older who have an overactive bladder caused by a certain nerve disorder (eg, spina bifida).
Oxibutinina EG is available only with your doctor's prescription.
Oxibutinina EG indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Oxibutinina EG Chloride is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
Oxibutinina EG Chloride Extended Release Tablets are also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida).
How should I use Oxibutinina EG?
Use Oxibutinina EG gel as directed by your doctor. Check the label on the medicine for exact dosing instructions.
An extra patient leaflet is available with Oxibutinina EG gel. Talk to your pharmacist if you have questions about this information.
Oxibutinina EG gel is for external use only. Do not get it in your eyes, nose, or mouth. If you get it in any of these areas, rinse right away with warm water.
Apply Oxibutinina EG gel to clean, dry, undamaged skin on the stomach, upper arms, shoulders, or thighs. If you apply Oxibutinina EG gel to the stomach, avoid the area around the belly button.
Application sites may be rotated to decrease the risk of skin reactions. Do not apply Oxibutinina EG gel to other areas of the body.
Do not apply Oxibutinina EG gel to skin with an open sore, scar, tattoo, or rash, or to an area that is irritated or has been recently shaved. Do not apply it to an area with a skin condition, such as eczema, seborrhea, or psoriasis.
Do not apply Oxibutinina EG gel to your breasts or genital areas.
Do not apply Oxibutinina EG gel to areas of the skin that have been treated with oils, lotions, or powders. However, you may use Oxibutinina EG gel with sunscreen.
Before using Oxibutinina EG gel for the first time, you must prime the pump. Do this by holding the pump upright and pressing down on the pump 4 times. Do not use any of the medicine that comes out of the pump during priming.
Wash your hands and the application site with mild soap and water before you apply Oxibutinina EG gel. Allow the area to dry completely.
Place your hand under the pump and press the pump down 3 times or as directed by your doctor. You can also place the pump right over the application site to dispense your dose. Gently rub Oxibutinina EG gel into your skin until it dries. Do not continue to rub after it dries.
Apply Oxibutinina EG gel right after you dispense your dose from the pump.
Wash your hands immediately after using Oxibutinina EG gel.
Do not bathe, swim, shower, exercise, or get the application site wet for at least 1 hour after using Oxibutinina EG gel.
Be careful not to get Oxibutinina EG gel on another person. If another person may come into contact with the application site, cover the area with clothing after the medicine dries.
Continue to use Oxibutinina EG gel even if your condition improves. Do not miss any doses.
If you miss a dose of Oxibutinina EG gel, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use Oxibutinina EG gel.
Uses of Oxibutinina EG in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
Use: Labeled Indications
Overactive bladder: Treatment of symptoms associated with overactive bladder (eg, urge urinary incontinence, urgency, frequency, urinary leakage, dysuria); treatment of symptoms associated with overactive bladder due to a neurological condition (eg, spina bifida) in patients ≥6 years of age (extended-release tablet only).
Off Label Uses
Primary focal hyperhidrosis
Data from randomized, placebo-controlled trials with limited numbers of patients and of short duration suggest that Oxibutinina EG may be beneficial for treatment of primary hyperhidrosis.
Oxibutinina EG description
Oxibutinina EG is an anticholinergic medication used to relieve urinary and bladder difficulties, including frequent urination and inability to control urination, by decreasing muscle spasms of the bladder. It competitively antagonizes the M1, M2, and M3 subtypes of the muscarinic acetylcholine receptor.
Oxibutinina EG dosage
Oxibutinina EG Dosage
Generic name: Oxibutinina EG CHLORIDE 100mg in 1g
Dosage form: gel
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
The contents of one sachet of Oxibutinina EG should be applied once daily to dry, intact skin on the abdomen, upper arms/shoulders, or thighs. Application sites should be rotated. Application of Oxibutinina EG should not be made to the same site on consecutive days.
Oxibutinina EG is for topical application only and should not be ingested.
More about Oxibutinina EG (Oxibutinina EG)
Side Effects
During Pregnancy
Dosage Information
Drug Interactions
Support Group
Pricing & Coupons
En Espanol
6 Reviews - Add your own review/rating
Consumer resources
Oxibutinina EG
Oxibutinina EG gel
Oxibutinina EG topical
Oxibutinina EG (Advanced Reading)
Other brands: Ditropan, Oxibutinina EG, Oxytrol, Oxibutinina EG, More (1) »
The concomitant use of Oxibutinina EG with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.
Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide.
Mean Oxibutinina EG chloride plasma concentrations were approximately 2 fold higher when Oxibutinina EG was administered with ketoconazole, a potent CYP3A4 inhibitor. Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter Oxibutinina EG mean pharmacokinetic parameters (i.e., C and AUC). The clinical relevance of such potential interactions is not known. Caution should be used when such drugs are co-administered.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.
The safety of Oxibutinina EG was evaluated in 626 patients (210 randomized to Oxibutinina EG 56 mg/day, 214 randomized to Oxibutinina EG 84 mg/day and 202 randomized to placebo) during a randomized, placebo-controlled, double-blind, 12-week clinical efficacy and safety study. A subset of these 626 patients (N = 77) participated in the 24-week open-label safety extension that followed the placebo-controlled study. Of the 77 patients in the safety extension, 24 were randomized to placebo gel during the double-blind, placebo-controlled 12-week study. In the combined double-blind, placebo-controlled study and the open-label safety extension, a total of 441 patients were exposed to at least one dose of Oxibutinina EG. 364 patients received at least 12 weeks of Oxibutinina EG treatment and 66 patients received an additional 24 weeks of Oxibutinina EG treatment during the open-label safety extension. The study population primarily consisted of women (87%) of Caucasian descent (87%) with an average age of 59 years who had overactive bladder with urge urinary incontinence.
Table 1 lists adverse reactions (ARs), regardless of causality, that were reported in the randomized, double-blind, placebo-controlled 12-week study at an incidence greater than placebo and in greater than 3% of patients treated with Oxibutinina EG.
Overall, 672 ARs were experienced by 51.9% of patients. Majority of the ARs were mild to moderate in intensity. The AR most commonly reported was dry mouth which was experienced by a greater proportion of patients in the Oxibutinina EG group than the placebo group (26 patients [12.1%] in the Oxibutinina EG 84 mg group, 10 patients [5.0%] in the placebo group). Application site erythema was the next most commonly reported AR (8 patients [3.7%] in the Oxibutinina EG 84 mg group and 2 patients [1.0%] in the placebo group). Other commonly reported ARs experienced by more patients in the Oxibutinina EG groups compared with placebo were application site rash (7 patients [3.3%] in the Oxibutinina EG 84 mg group and 1 patient [0.5%] in the placebo group); application site pruritus (6 patients [2.8%] in the Oxibutinina EG 84 mg group and 1 patient [0.5%] in the placebo group). The overall rate of application site adverse reactions of any kind was 14.2% in patients receiving Oxibutinina EG as compared to 3.7% in patients receiving placebo. Other cholinergic AEs < 2% in occurrence include dry eyes and blurred vision.
There were no deaths during the study. There were no clinically meaningful changes in vital signs, laboratory values, or ECG examinations over the course of the study.
Table 1: Commonly Reported Adverse Reactions that were reported In greater than 3% of patients treated with Oxibutinina EG and at an incidence greater than placebo.
Preferred Term Each patient is counted only once within each treatment, body system and preferred term. All percentages are based on number of patients in the ITT population within each treatment group as denominator.
During the 24-week open-label safety extension, the most commonly reported ARs were urinary tract infection and nasopharyngitis reported in 4 patients each (5.2%), followed by conjunctivitis and application site erythema (both occurred in 3 patients [3.9%]). One patient prematurely discontinued due to the application site erythema and pruritus (both considered to be of mild severity).
You should not use this medication if you are allergic to Oxibutinina EG, or if you have uncontrolled narrow-angle glaucoma, a blockage in your digestive tract, if you have decreased urination, or if you are unable to urinate.
Before using Oxibutinina EG topical, tell your doctor if you have urination problems, glaucoma, liver or kidney disease, myasthenia gravis, severe constipation, ulcerative colitis or other intestinal disorder, gastroesophageal reflux disease (GERD), or slow digestion.
Do not bathe, shower, swim, use a hot tub, or exercise vigorously for at least 1 hour after applying this medication.
It is best to cover treated skin areas with clothing after the gel has dried completely. This will help prevent getting this medicine on your other skin or on other people.
Oxibutinina EG gel is flammable. Avoid using near open flame, and do not smoke until the gel has completely dried on your skin.
This medication may cause blurred vision and may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert and able to see clearly.
Drinking alcohol can increase certain side effects of Oxibutinina EG topical.
Avoid becoming overheated or dehydrated during exercise and in hot weather. Drink plenty of fluids to keep yourself hydrated while you are using Oxibutinina EG topical.
DailyMed. "OXYBUTYNIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Oxibutinina EG are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Oxibutinina EG. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
Consumer reported price estimates
No survey data has been collected yet
1 consumer reported time for results
To what extent do I have to use Oxibutinina EG before I begin to see changes in my health conditions? As part of the reports released by ndrugs.com website users, it takes > 3 month and a few days before you notice an improvement in your health conditions. Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Oxibutinina EG. To get the time effectiveness of using Oxibutinina EG drug by other patients, please click here.
Users
%
> 3 month
1
100.0%
1 consumer reported age
Users
%
> 60
1
100.0%
Consumer reviews
There are no reviews yet. Be the first to write one!
